Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues
- PMID: 21518717
- PMCID: PMC3081183
- DOI: 10.1542/peds.2010-2217
Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues
Erratum in
- Pediatrics. 2011 Aug;128(2):390
Abstract
Background: Guidelines for prevention of group B streptococcal (GBS) infection have successfully reduced early onset (EO) GBS disease. Study results suggest that Escherichia coli is an important EO pathogen.
Objective: To determine EO infection rates, pathogens, morbidity, and mortality in a national network of neonatal centers.
Methods: Infants with EO infection were identified by prospective surveillance at Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Network centers. Infection was defined by positive culture results for blood and cerebrospinal fluid obtained from infants aged ≤72 hours plus treatment with antibiotic therapy for ≥5 days. Mother and infant characteristics, treatments, and outcomes were studied. Numbers of cases and total live births (LBs) were used to calculate incidence.
Results: Among 396 586 LBs (2006-2009), 389 infants developed EO infection (0.98 cases per 1000 LBs). Infection rates increased with decreasing birth weight. GBS (43%, 0.41 per 1000 LBs) and E coli (29%, 0.28 per 1000 LBs) were most frequently isolated. Most infants with GBS were term (73%); 81% with E coli were preterm. Mothers of 67% of infected term and 58% of infected preterm infants were screened for GBS, and results were positive for 25% of those mothers. Only 76% of mothers with GBS colonization received intrapartum chemoprophylaxis. Although 77% of infected infants required intensive care, 20% of term infants were treated in the normal newborn nursery. Sixteen percent of infected infants died, most commonly with E coli infection (33%).
Conclusion: In the era of intrapartum chemoprophylaxis to reduce GBS, rates of EO infection have declined but reflect a continued burden of disease. GBS remains the most frequent pathogen in term infants, and E coli the most significant pathogen in preterm infants. Missed opportunities for GBS prevention continue. Prevention of E coli sepsis, especially among preterm infants, remains a challenge.
References
-
- McCracken GH., Jr Group B streptococci: The new challenge in neonatal infections. J Pediatr. 1973;82(4):703–706 - PubMed
-
- Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342(1):15–20 - PubMed
-
- Centers for Disease Control and Prevention (CDC). Early onset and late-onset neonatal group B streptococcal disease: United States, 1996–2004. MMWR Morb Mortal Wkly Rep. 2005;54(47):1205–1208 - PubMed
-
- Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;51(RR-11):1–22 - PubMed
-
- Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA. 2008;299(17):2056–2065 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 HD27851/HD/NICHD NIH HHS/United States
- U10 HD021385/HD/NICHD NIH HHS/United States
- U10 HD053124/HD/NICHD NIH HHS/United States
- U10 HD021364/HD/NICHD NIH HHS/United States
- M01RR32/RR/NCRR NIH HHS/United States
- U10 HD53089/HD/NICHD NIH HHS/United States
- U10 HD27853/HD/NICHD NIH HHS/United States
- U01 HD36790/HD/NICHD NIH HHS/United States
- U10 HD21385/HD/NICHD NIH HHS/United States
- U10 HD034216/HD/NICHD NIH HHS/United States
- UL1 RR24139/RR/NCRR NIH HHS/United States
- U10 HD027856/HD/NICHD NIH HHS/United States
- U10 HD40689/HD/NICHD NIH HHS/United States
- U10 HD021373/HD/NICHD NIH HHS/United States
- UL1 RR024139/RR/NCRR NIH HHS/United States
- UL1 RR025764/RR/NCRR NIH HHS/United States
- U10 HD53119/HD/NICHD NIH HHS/United States
- M01 RR59/RR/NCRR NIH HHS/United States
- U10 HD053119/HD/NICHD NIH HHS/United States
- U10 HD53124/HD/NICHD NIH HHS/United States
- U10 HD21364/HD/NICHD NIH HHS/United States
- U01 HD036790/HD/NICHD NIH HHS/United States
- M01 RR6022/RR/NCRR NIH HHS/United States
- P20 RR011104/RR/NCRR NIH HHS/United States
- U10 HD34216/HD/NICHD NIH HHS/United States
- U10 HD027880/HD/NICHD NIH HHS/United States
- M01 RR70/RR/NCRR NIH HHS/United States
- U10 HD053109/HD/NICHD NIH HHS/United States
- U10 HD27880/HD/NICHD NIH HHS/United States
- M01 RR008084/RR/NCRR NIH HHS/United States
- UL1 TR001449/TR/NCATS NIH HHS/United States
- UG1 HD053089/HD/NICHD NIH HHS/United States
- U10 HD27904/HD/NICHD NIH HHS/United States
- M01 RR633/RR/NCRR NIH HHS/United States
- U10 HD53109/HD/NICHD NIH HHS/United States
- U10 HD040689/HD/NICHD NIH HHS/United States
- U10 HD040492/HD/NICHD NIH HHS/United States
- M01 RR64/RR/NCRR NIH HHS/United States
- U10 HD027853/HD/NICHD NIH HHS/United States
- U10 HD027904/HD/NICHD NIH HHS/United States
- U10 HD27856/HD/NICHD NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- U10HD27871/HD/NICHD NIH HHS/United States
- M01RR8084/RR/NCRR NIH HHS/United States
- U10 HD027871/HD/NICHD NIH HHS/United States
- 5P20RR11104/RR/NCRR NIH HHS/United States
- UL1 TR000041/TR/NCATS NIH HHS/United States
- U10 HD027851/HD/NICHD NIH HHS/United States
- M01 RR750/RR/NCRR NIH HHS/United States
- UL1 RR25764/RR/NCRR NIH HHS/United States
- M01 RR54/RR/NCRR NIH HHS/United States
- U10 HD21373/HD/NICHD NIH HHS/United States
- UL1 RR025008/RR/NCRR NIH HHS/United States
- MO1RR125/RR/NCRR NIH HHS/United States
- M01 RR006022/RR/NCRR NIH HHS/United States
- U10 HD053089/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases